Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination

被引:77
作者
Castanheira, Mariana [1 ]
Deshpande, Lalitagauri M. [1 ]
Messer, Shawn A. [1 ]
Rhomberg, Paul R. [1 ]
Pfaller, Michael A. [1 ]
机构
[1] JMI Labs, Beaver Kreek Ctr 345, North Liberty, IA 52317 USA
关键词
Azoles; Yeast; Resistance mechanism; Candida tropicalis; Candida parapsilosis; Antifungal susceptibility testing; FLUCONAZOLE RESISTANCE; ECHINOCANDIN RESISTANCE; FKS MUTATIONS; CHANGING EPIDEMIOLOGY; MOLECULAR-MECHANISMS; SUSCEPTIBILITY; IDENTIFICATION; INFECTIONS; COLLECTION; EMERGENCE;
D O I
10.1016/j.ijantimicag.2019.09.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study evaluated the activity of echinocandins, azoles and amphotericin B against Candida spp. isolates and other yeasts and characterised azole resistance mechanisms in Candida parapsilosis and Candida tropicalis. Invasive Candida spp. isolates (n = 2936) collected in 60 hospitals worldwide during 20162017 underwent antifungal susceptibility testing by broth microdilution. Azole-resistant C. parapsilosis and C. tropicalis were submitted to qPCR for ERG11, CDR1 and MDR1, and the whole genome sequence was analysed. Results of non-susceptibility to echinocandins ranged from 0.0-2.3%, being highest in Candida glabrata. More than 99.0% of the Candida albicans isolates were susceptible to both fluconazole and voriconazole. Fluconazole resistance in C. glabrata was 6.5% overall, being highest in the USA (13.0%). Resistance to voriconazole in Candida krusei was only noted in the USA (5.0%). Azoles inhibited 89.1-91.6% of C. parapsilosis isolates, with most resistant isolates noted in Europe (15.1%), including 36 isolates from Italy (three hospitals), of which 34 harboured Erg11 Y132F mutations and overexpressed MDR1. Azole non-wild-type C. tropicalis (7/227) were found in five countries: 3 isolates from Thailand had the same Erg11 Y132F alteration. Fluconazole non-wild-type isolates were noted among 3/77 (3.9%) Candida dubliniensis, 4/17 (23.5%) Candida guilliermondii, 4/47 (8.5%) Candida lusitaniae and other less common yeast species. Echinocandin use has been recommended over fluconazole for invasive Candida infections. However, azoles are still active against the most common Candida spp. and resistance appears to be restricted to certain geographic regions and associated with Erg11 Y132 alterations in C. parapsilosis and C. tropicalis. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页数:10
相关论文
共 39 条
  • [11] Chapman B, 2017, J ANTIMICROB CHEMOTH, V72, P1103, DOI 10.1093/jac/dkw422
  • [12] Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea
    Choi, Yong Jun
    Kim, Yae-Jean
    Yong, Dongeun
    Byun, Jung-Hyun
    Kim, Taek Soo
    Chang, Yun Sil
    Choi, Min Ji
    Byeon, Seung Ah
    Won, Eun Jeong
    Kim, Soo Hyun
    Shin, Myung Geun
    Shin, Jong Hee
    [J]. EMERGING INFECTIOUS DISEASES, 2018, 24 (09) : 1768 - 1770
  • [13] Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit
    Chow, Jennifer K.
    Golan, Yoav
    Ruthazer, Robin
    Karchmer, Adolf W.
    Carmeli, Yehuda
    Lichtenberg, Deborah
    Chawla, Varun
    Young, Janet
    Hadley, Susan
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (08) : 1206 - 1213
  • [14] Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011
    Cleveland, Angela Ahlquist
    Farley, Monica M.
    Harrison, Lee H.
    Stein, Betsy
    Hollick, Rosemary
    Lockhart, Shawn R.
    Magill, Shelley S.
    Derado, Gordana
    Park, Benjamin J.
    Chiller, Tom M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 (10) : 1352 - 1361
  • [15] Clinical and Laboratory Standards Institute, 2017, Reference method for broth dilution antifungal susceptibility testing of yeasts
  • [16] CLSI, 2017, CLSI supplement M60.
  • [17] CLSI, 2012, M27S4 CLSI
  • [18] Candida tropicalis Antifungal Cross-Resistance Is Related to Different Azole Target (Erg11p) Modifications
    Forastiero, A.
    Mesa-Arango, A. C.
    Alastruey-Izquierdo, A.
    Alcazar-Fuoli, L.
    Bernal-Martinez, L.
    Pelaez, T.
    Lopez, J. F.
    Grimalt, J. O.
    Gomez-Lopez, A.
    Cuesta, I.
    Zaragoza, O.
    Mellado, E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 4769 - 4781
  • [19] Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa
    Govender, Nelesh P.
    Patel, Jaymati
    Magobo, Rindidzani E.
    Naicker, Serisha
    Wadula, Jeannette
    Whitelaw, Andrew
    Coovadia, Yacoob
    Kularatne, Ranmini
    Govind, Chetna
    Lockhart, Shawn R.
    Zietsman, Inge L.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (07) : 1994 - 2004
  • [20] Changing epidemiology of candidemia in a medical center in middle Taiwan
    Hii, Ing-Moi
    Chang, Hui-Lan
    Lin, Li-Chen
    Lee, Yu-Lin
    Liu, Yuag-Meng
    Liu, Chun-Eng
    Chen, Chang-Hua
    Cheng, Yu-Ren
    Chang, Chih-Yen
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2015, 48 (03) : 306 - 315